Laurent Eckert

11.9k total citations · 5 hit papers
95 papers, 5.0k citations indexed

About

Laurent Eckert is a scholar working on Dermatology, Physiology and Immunology and Allergy. According to data from OpenAlex, Laurent Eckert has authored 95 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 67 papers in Dermatology, 55 papers in Physiology and 51 papers in Immunology and Allergy. Recurrent topics in Laurent Eckert's work include Dermatology and Skin Diseases (65 papers), Asthma and respiratory diseases (55 papers) and Allergic Rhinitis and Sensitization (43 papers). Laurent Eckert is often cited by papers focused on Dermatology and Skin Diseases (65 papers), Asthma and respiratory diseases (55 papers) and Allergic Rhinitis and Sensitization (43 papers). Laurent Eckert collaborates with scholars based in United States, France and Germany. Laurent Eckert's co-authors include Neil M.H. Graham, Abhijit Gadkari, Gianluca Pirozzi, A. Gadkari, Eric L. Simpson, Marjolein de Bruin‐Weller, S. Barbarot, Eric L. Simpson, S. Auziere and Marius Ardeleanu and has published in prestigious journals such as The Lancet, Circulation and Gastroenterology.

In The Last Decade

Laurent Eckert

93 papers receiving 4.9k citations

Hit Papers

Dupilumab efficacy and safety in adults with uncontrolled... 2016 2026 2019 2022 2016 2018 2017 2021 2019 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial
    2016 632 citations Sally E. Wenzel, Mario Castro et al. The Lancet profile →
  2. Epidemiology of atopic dermatitis in adults: Results from an international survey
    2018 574 citations S. Barbarot, S. Auziere et al. profile →
  3. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t
    2017 344 citations Marjolein de Bruin‐Weller, Diamant Thaçi et al. British Journal of Dermatology profile →
  4. Atopic dermatitis in the pediatric population
    2021 255 citations Jonathan I. Silverberg, S. Barbarot et al. Annals of Allergy Asthma & Immunology profile →
  5. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis
    2019 231 citations Gil Yosipovitch, Matthew Reaney et al. British Journal of Dermatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Laurent Eckert United States 33 3.3k 3.0k 2.3k 609 592 95 5.0k
Jorge Máspero United States 29 358 0.1× 1.6k 0.5× 3.9k 1.7× 305 0.5× 1.1k 1.8× 136 4.7k
Μichael Μakris Greece 26 522 0.2× 543 0.2× 348 0.2× 445 0.7× 365 0.6× 113 2.5k
Pierluigi Paggiaro Italy 29 187 0.1× 571 0.2× 2.8k 1.2× 144 0.2× 442 0.7× 101 3.7k
David A. Mathison United States 22 153 0.0× 639 0.2× 1.9k 0.8× 287 0.5× 253 0.4× 45 3.1k
Yun Chon United States 21 174 0.1× 199 0.1× 1.1k 0.5× 480 0.8× 950 1.6× 45 2.8k
Anneke Ten Brinke Netherlands 27 115 0.0× 1.1k 0.4× 4.3k 1.9× 222 0.4× 940 1.6× 73 4.9k
Joo‐Hee Kim South Korea 22 196 0.1× 321 0.1× 512 0.2× 220 0.4× 185 0.3× 189 1.9k
Tmirah Haselkorn United States 34 107 0.0× 641 0.2× 2.4k 1.0× 131 0.2× 378 0.6× 85 3.6k
James Piercy United Kingdom 23 321 0.1× 241 0.1× 249 0.1× 378 0.6× 302 0.5× 102 2.2k
Y. H. Chan Singapore 22 631 0.2× 276 0.1× 154 0.1× 256 0.4× 232 0.4× 41 1.8k

Countries citing papers authored by Laurent Eckert

Since Specialization
Citations

This map shows the geographic impact of Laurent Eckert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laurent Eckert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laurent Eckert more than expected).

Fields of papers citing papers by Laurent Eckert

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laurent Eckert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laurent Eckert. The network helps show where Laurent Eckert may publish in the future.

Co-authorship network of co-authors of Laurent Eckert

This figure shows the co-authorship network connecting the top 25 collaborators of Laurent Eckert. A scholar is included among the top collaborators of Laurent Eckert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laurent Eckert. Laurent Eckert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Barbarot, S., Abhijit Gadkari, Eric L. Simpson, et al.. (2022). The Family Impact of Atopic Dermatitis in the Pediatric Population: Results from an International Cross-sectional Study. The Journal of Pediatrics. 246. 220–226.e5. 30 indexed citations
2.
Silverberg, Jonathan I., S. Barbarot, Abhijit Gadkari, et al.. (2021). Atopic dermatitis in the pediatric population. Annals of Allergy Asthma & Immunology. 126(4). 417–428.e2. 255 indexed citations breakdown →
3.
Barbarot, S., Andreas Wollenberg, Jonathan I. Silverberg, et al.. (2020). Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase 3 trials. Journal of Dermatological Treatment. 33(1). 266–277. 14 indexed citations
4.
Beck, Lisa A., Jonathan I. Silverberg, Eric L. Simpson, et al.. (2020). Dupilumab significantly improves sleep outcomes in adult patients with atopic dermatitis: results from five randomized clinical trials. Journal of the European Academy of Dermatology and Venereology. 35(2). e130–e133. 9 indexed citations
5.
Barbarot, S., Jonathan I. Silverberg, Abhijit Gadkari, et al.. (2020). 15021 The family impact of atopic dermatitis in children aged 6-11 years: A cross-sectional study in the United States, Canada, Europe, and Japan. Journal of the American Academy of Dermatology. 83(6). AB27–AB27.
6.
Cork, Michael J., Lawrence F. Eichenfield, Andrew Blauvelt, et al.. (2019). 605 Efficacy and safety of dupilumab in adolescent patients with moderate-to-severe atopic dermatitis. Journal of Investigative Dermatology. 139(5). S104–S104. 1 indexed citations
7.
Boguniewicz, Mark, Diamant Thaçi, Peter Lio, et al.. (2019). Dupilumab Improves Outcomes of Concurrent Asthma and Chronic Sino-Nasal Conditions in Patients With Atopic Dermatitis—a Pooled Analysis of Four Phase 3 Studies (LIBERTY AD SOLO 1 & 2, CHRONOS, and CAFÉ). Journal of Allergy and Clinical Immunology. 143(2). AB123–AB123. 4 indexed citations
8.
Ariëns, Lieneke F.M., Abhijit Gadkari, Harmieke van Os‐Medendorp, et al.. (2019). Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index. Acta Dermato Venereologica. 99(10). 851–857. 14 indexed citations
9.
Paller, Amy S., Ashish Bansal, Eric L. Simpson, et al.. (2019). Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial. American Journal of Clinical Dermatology. 21(1). 119–131. 55 indexed citations
10.
11.
Gebauer, Kurt, Diana Rubel, Mette Deleuran, et al.. (2019). Safety and efficacy of open-label dupilumab in adult patients with atopic dermatitis: An interim analysis at week 76. UWA Profiles and Research Repository (University of Western Australia). 49. 19–19. 1 indexed citations
12.
Simpson, Eric L., Marjolein de Bruin‐Weller, Laurent Eckert, et al.. (2019). Responder Threshold for Patient-Oriented Eczema Measure (POEM) and Children’s Dermatology Life Quality Index (CDLQI) in Adolescents with Atopic Dermatitis. Dermatology and Therapy. 9(4). 799–805. 27 indexed citations
13.
Thaçi, Diamant, Eric L. Simpson, Mette Deleuran, et al.. (2019). Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). Journal of Dermatological Science. 94(2). 266–275. 134 indexed citations
14.
Girolomoni, Giampiero, A. Gadkari, S. Auziere, et al.. (2017). The Patient-Reported Disease Burden In Adults With Atopic Dermatitis: A Cross-Sectional Study In Canada and Europe. Value in Health. 20(9). A807–A807. 5 indexed citations
15.
Zuidgeest, Mira G. P., Paco M J Welsing, Ghislaine J. M. W. van Thiel, et al.. (2017). Series: Pragmatic trials and real world evidence: Paper 5. Usual care and real life comparators. Journal of Clinical Epidemiology. 90. 92–98. 32 indexed citations
16.
Villeneuve, Sylvia, A. Gadkari, Steven Blackburn, et al.. (2016). Disease Severity and Control in Adults with a History of Moderate to Severe Atopic Dermatitis: Results from a Large Patient-Physician Survey in the United Kingdom, Germany, and France. Value in Health. 19(7). A596–A596. 4 indexed citations
17.
Wenzel, Sally E., Mario Castro, Jonathan Corren, et al.. (2016). Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. The Lancet. 388(10039). 31–44. 632 indexed citations breakdown →
18.
Carita, Paulo, et al.. (2010). Abstract 16188: A Comparative Analysis of Cost and Cost-effectiveness of Rhythm vs. Rate Control Strategies in the Treatment of Atrial Fibrillation Patients. Circulation. 1 indexed citations
19.
Eckert, Laurent & Bruno Falissard. (2006). Using meta-regression in performing indirect-comparisons: comparing escitalopram with venlafaxine XR. Current Medical Research and Opinion. 22(11). 2313–2321. 13 indexed citations
20.
Eckert, Laurent & Christophe Lançon. (2006). Duloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisons. BMC Psychiatry. 6(1). 30–30. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jorge Máspero Breakdown of academic impact, for papers by Μichael Μakris Breakdown of academic impact, for papers by Pierluigi Paggiaro Breakdown of academic impact, for papers by David A. Mathison Breakdown of academic impact, for papers by Yun Chon Breakdown of academic impact, for papers by Anneke Ten Brinke Breakdown of academic impact, for papers by Joo‐Hee Kim Breakdown of academic impact, for papers by Tmirah Haselkorn Breakdown of academic impact, for papers by James Piercy Breakdown of academic impact, for papers by Y. H. Chan
Rankless by CCL
2026